PROF Earnings Date: Nov 5, 2026 (Estimated) — Profound Medical Corp.
NASDAQ · Healthcare · Medical Devices
Updated
When is PROF's next earnings date?
Profound Medical Corp. (PROF) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.19 on revenue of $8.8M.
How did PROF do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Profound Medical Corp. posted EPS of -$0.26 versus the -$0.22 estimate, a miss of 8.3%. Revenue was $2.5M against a $4.8M estimate. The stock's 1-day post-earnings move was -6.7%.
How much does PROF stock move after earnings?
PROF beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.3% (up or down) in the day after earnings.
About Profound Medical Corp.
Profound Medical Corp., through its subsidiaries, is a commercial-stage medical technology firm specializing in the development of magnetic resonance (MR)-guided ablation solutions. These innovative procedures are designed to treat conditions such as prostate disease and uterine fibroids, as well as providing palliative pain relief. The company markets its solutions across Canada, Germany, the United States, and Finland. Its flagship product, the TULSA-PRO system, is specifically designed for use with magnetic resonance imaging (MRI) scanners within hospital settings and other treatment centers. Additionally, Profound Medical offers Sonalleve, a therapeutic platform that addresses uterine fibroids – including through non-invasive methods – and provides palliative relief for pain linked to bone metastases. The company's primary operations are headquartered in Mississauga, Canada.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.22 | -0.26 | -8.33% | $2.5M | ❌ Miss | -6.68% | -15.99% | -13.22% |
| 2026-05-07 | Q1 2026 | -0.25 | -0.19 | +24.00% | $5.3M | ✅ Beat | -4.33% | +0.56% | -8.24% |
| 2026-03-05 | Q4 2025 | -0.27 | -0.27 | +0.00% | $6.0M | ➖ Inline | -29.11% | -25.90% | -12.42% |
| 2025-11-13 | Q3 2025 | -0.38 | -0.26 | +31.58% | $5.3M | ✅ Beat | +7.87% | -7.48% | +21.10% |
| 2025-08-14 | Q2 2025 | -0.41 | -0.52 | -26.83% | $2.2M | ❌ Miss | -23.29% | -16.97% | -26.17% |
| 2025-03-06 | Q4 2024 | -0.30 | -0.20 | +33.33% | $4.2M | ✅ Beat | -5.90% | -3.98% | -31.41% |
| 2024-11-07 | Q3 2024 | -0.30 | -0.38 | -26.67% | $2.8M | ❌ Miss | -2.34% | -10.59% | -14.96% |
| 2024-03-07 | Q4 2023 | -0.32 | -0.42 | -31.25% | $2.0M | ❌ Miss | -10.86% | -5.43% | -7.87% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $2.5M total
| Segment | Share | Revenue | YoY | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|
| Recurring - Non-Capital | 64.9% | $1.6M | +3.3% | $1.6M | $4.1M | $2.3M | $2.5M |
| Capital Equipment | 35.1% | $871K | +34.0% | $650K | $1.2M | $3.7M | $2.9M |
By region
Q2 FY26 · $2.5M total
| Segment | Share | Revenue | YoY | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 70.3% | $1.7M | -11.7% | $2.0M | $5.0M | $3.7M | $1.6M |
| CANADA | 22.4% | $556K | -2.5% | $570K | $570K | $1.9M | $3.6M |
| GERMANY | 7.3% | $182K | +30.0% | $140K | $168K | $465K | $150K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.